Motric Bio

Executive Summary

Motric Bio is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing novel oral small-molecule therapies for movement disorders, including dystonia and spasticity. Founded in 2021, the company addresses a significant unmet need by targeting overactive skeletal muscle directly and selectively to alleviate pathological contractions and involuntary movements. Its lead program is believed to be in Phase 2 clinical development, with a mechanism of action that offers potential advantages over current standard-of-care treatments, such as improved tolerability and oral bioavailability. The company's approach is differentiated by its focus on muscle-selective inhibition, which could reduce systemic side effects. Though early-stage and private, Motric Bio has attracted attention from investors and partners due to the large addressable market and the lack of effective, non-sedating therapies. Key near-term milestones include Phase 2 data readouts and potential regulatory interactions. The company's success hinges on demonstrating clinical proof-of-concept and safety in ongoing trials.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 topline data for lead candidate in dystonia40% success
• Q1 2027Initiation of Phase 2 trial for spasticity indication60% success
• TBDPotential partnership or licensing agreement for ex-US rights30% success